Real-world clinical outcomes, patient characteristics, and treatment patterns among patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative, claudin-18 isoform 2-positive gastric or gastroesophageal junction adenocarcinoma treated with zolbetuximab or other first line treatments: A cohort study using secondary data in Europe and Canada (RADIANCE)

ENCePP Code of conduct

N/A

Data sources

• Data source(s), other:
  Oncology Outcomes; SAPHIR; AGAMENON; The Swedish National Register for Esophageal and Gastric Cancer; Electronic Medical Record-enabled sites;
• Data sources (types):
  Administrative healthcare records (e.g., claims)

  Cancer registry

  Electronic healthcare records (EHR)

  Pharmacy dispensing records

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No